Jazz Pharmaceuticals (JAZZ) Non-Current Assets (2010 - 2026)

Jazz Pharmaceuticals has reported Non-Current Assets for 17 years, with the latest figure at $7.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 1.76% year-over-year to $7.3 billion; the trailing twelve-month figure through Mar 2026 stood at $30.0 billion (down 1.22% YoY), and the FY2025 full-year result was $7.5 billion, up 1.49% from the prior year.
• Non-Current Assets for Q1 2026 stood at $7.3 billion, down from $7.5 billion in the prior quarter.
• The five-year high for Non-Current Assets was $9.3 billion in Q1 2022, with the low at $7.3 billion in Q1 2026.
• Average Non-Current Assets over 5 years is $7.9 billion, with a median of $7.8 billion recorded in 2022.
• Peak annual rise in Non-Current Assets reached 158.19% in 2022, while the deepest fall reached 20.68% in 2022.
• Tracing JAZZ's Non-Current Assets over 5 years: stood at $8.2 billion in 2022, then retreated by 3.3% to $8.0 billion in 2023, then decreased by 7.22% to $7.4 billion in 2024, then rose by 1.49% to $7.5 billion in 2025, then fell by 2.89% to $7.3 billion in 2026.
• The last three Non-Current Assets figures came in at $7.3 billion (Q1 2026), $7.5 billion (Q4 2025), and $7.6 billion (Q3 2025), per Business Quant data.

Peer Comparison